TY - JOUR
T1 - Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents
T2 - A delphi survey of oncology pharmacists
AU - Chan, Alexandre
AU - Tan, Seow Hwei
AU - Wong, Chen May
AU - Yap, Kevin Yi Lwern
AU - Ko, Yu
N1 - Funding Information:
We thank the Department of Pharmacy, National University of Singapore, Singapore, for providing Final Year Project funding for this study and we appreciate the assistance of survey administrators from the computer center, National University of Singapore: Balam-ba Karagada and Pingan Cao. We also extend our gratitude and appreciation to the panel of oncology pharmacists for their valuable time and participation in the survey. The members of the expert panel included (in alphabetical order by surname): Joseph Bubalo, PharmD, BCPS, BCOP; Rami B. Ibrahim, MSc, PharmD, BCPS, BCOP; Robert J. Ignoffo, PharmD, FASHP, FCSHP; Jill Kolesar, PharmD, BCPS, FCCP; Jude Lee, BPharm; Masha Lam, PharmD, BCOP; Gina Dolores Policarpo, PharmD; Vivianne Shih, BscPharm (Hons), BCPS, BCOP; and Suphat Subongkot, PharmD, BCPS, BCOP.
PY - 2009
Y1 - 2009
N2 - Background: Drug-drug interactions (DDIs) can lead to adverse clinical outcomes, particularly in oncology, because of the narrow therapeutic index of chemotherapeutic agents and because patients with cancer are at a high risk due to polypharmacy and age-related organ dysfunction. In a previously published study, drug profiles were developed based on primary and tertiary literature reviews for a list of clinically significant DDIs involving 28 oral anticancer agents (OAAs). Objective: This study was based on a Delphi survey of oncology pharmacists; the survey results were used to develop a consensus list of clinically significant DDIs involving OAAs and nonanticancer agents. Methods: In this study, the DDI profiles previously developed were updated, and the DDI pairs that were listed both in the 2009 Drug Interaction Facts (DIF) and the Thomson Micromedex DrugDex System compendia and that also met the predetermined criteria for clinical significance were selected for further evaluation. In a 2-round, electronically administered Delphi survey of oncology pharmacists, a 5-point Likert scale (1-5, where 1 = strongly agree and 5 = strongly disagree) was used to evaluate the DDI pairs based on 8 clinical aspects (clinical importance; irreversible morbidity and mortality; quality of data; quantity of data; patient's organ functions; comorbid conditions; awareness of interaction; and management burden). International pharmacists who specialized in oncology pharmacy practice and had ≥5 years of practice experience were eligible to participate. Results: Nine of the 23 surveyed pharmacists responded, giving a response rate of 39.1%. A total of 37 DDI pairs were selected from DIF and DrugDex and evaluated by the survey respondents, resulting in the identification, via consensus, of 12 clinically significant DDI pairs. The clinical aspects with the most DDIs that reached consensus of agreement were clinical importance (82.9%) and awareness of interaction (73.2%). Conclusion: An expert panel identified 12 clinically significant DDIs involving OAAs.
AB - Background: Drug-drug interactions (DDIs) can lead to adverse clinical outcomes, particularly in oncology, because of the narrow therapeutic index of chemotherapeutic agents and because patients with cancer are at a high risk due to polypharmacy and age-related organ dysfunction. In a previously published study, drug profiles were developed based on primary and tertiary literature reviews for a list of clinically significant DDIs involving 28 oral anticancer agents (OAAs). Objective: This study was based on a Delphi survey of oncology pharmacists; the survey results were used to develop a consensus list of clinically significant DDIs involving OAAs and nonanticancer agents. Methods: In this study, the DDI profiles previously developed were updated, and the DDI pairs that were listed both in the 2009 Drug Interaction Facts (DIF) and the Thomson Micromedex DrugDex System compendia and that also met the predetermined criteria for clinical significance were selected for further evaluation. In a 2-round, electronically administered Delphi survey of oncology pharmacists, a 5-point Likert scale (1-5, where 1 = strongly agree and 5 = strongly disagree) was used to evaluate the DDI pairs based on 8 clinical aspects (clinical importance; irreversible morbidity and mortality; quality of data; quantity of data; patient's organ functions; comorbid conditions; awareness of interaction; and management burden). International pharmacists who specialized in oncology pharmacy practice and had ≥5 years of practice experience were eligible to participate. Results: Nine of the 23 surveyed pharmacists responded, giving a response rate of 39.1%. A total of 37 DDI pairs were selected from DIF and DrugDex and evaluated by the survey respondents, resulting in the identification, via consensus, of 12 clinically significant DDI pairs. The clinical aspects with the most DDIs that reached consensus of agreement were clinical importance (82.9%) and awareness of interaction (73.2%). Conclusion: An expert panel identified 12 clinically significant DDIs involving OAAs.
KW - Delphi survey
KW - drug safety
KW - drug-drug interactions
KW - oral anticancer agents
UR - http://www.scopus.com/inward/record.url?scp=84983726617&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84983726617&partnerID=8YFLogxK
U2 - 10.1016/j.clinthera.2009.11.008
DO - 10.1016/j.clinthera.2009.11.008
M3 - Article
AN - SCOPUS:84983726617
SN - 0149-2918
VL - 31
SP - 2379
EP - 2386
JO - Clinical Therapeutics
JF - Clinical Therapeutics
IS - PART. 2
ER -
